Racha T. Khalaf

Racha T. Khalaf

Auto-generated profile, based on publicly available information

Racha T. Khalaf

Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition University of South Florida Morsani College of Medicine Tampa Florida USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
RKRacha T. Khalaf
Racha T. Khalaf
WRWenly Ruan
Wenly Ruan
SOSarah Orkin
Sarah Orkin
MWMichael Wilsey
Michael Wilsey
DFDouglas S. Fishman
Douglas S. Fishman
TWThomas Walker
Thomas Walker

22 November 2018 in Nutrition in Clinical Practice
Verified
Journal Article
Closed access
PDF file
RKRacha T. Khalaf
Racha T. Khalaf
DGDeanna Green
Deanna Green
EAErnest K. Amankwah
Ernest K. Amankwah
JPJacquelin Peck
Jacquelin Peck
VCVanessa Carr
Vanessa Carr
MWMichael Wilsey
Michael Wilsey

27 February 2025 in Seminars in Liver Disease
Verified
Journal Article
Open access
PDF file
SASasha-Jane Abi-Aad
Sasha-Jane Abi-Aad
MLMark Lovell
Mark Lovell
RKRacha T. Khalaf
Racha T. Khalaf
RSRonald J. Sokol
Ronald J. Sokol
Long-term parenteral nutrition (PN) has considerably improved the management of intestinal failure (IF) in children and adults, particularly those with short bowel syndrome; however, it carries a significant risk of hepatotoxicity, specifically, intestinal failure-associated liver disease (IFALD), also known as PN-associated liver disease. This review provides an update on the latest understanding of IFALD pathogenesis, emerging therapies, and ongoing challenges in the management of this complication. A number of factors are associated with the development of IFALD. PN lipid emulsions, phytosterol exposure, bacterial dysbiosis, an altered gut–liver axis, and episodes of sepsis disrupt bile acid homeostasis and promote liver inflammation in the active phase of IFALD, favoring the development of PN-associated cholestasis (PNAC) and the more chronic form of steatohepatitis with fibrosis. Based on the identification of pathophysiological pathways, potential therapies are being studied in preclinical and clinical trials, including lipid emulsion modifications; targeted therapies such as Farnesoid X receptor (FXR) and liver receptor homolog 1 (LRH-1) agonists, tumor necrosis factor inhibitors, glucagon-like peptide-2 analogs; microbiome modulation; and supplementation with choline and antioxidants. In conclusion, the pathogenesis of IFALD is complex, and PN dependence and liver injury remain challenging, particularly in patients with IF who cannot advance to enteral nutrition and be weaned off PN.

2 December 2020 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RKRacha T. Khalaf
Racha T. Khalaf
GFGlenn T. Furuta
Glenn T. Furuta
BWBrandie D. Wagner
Brandie D. Wagner
CRCharles E. Robertson
Charles E. Robertson
RARachel Andrews
Rachel Andrews
JHJ. Kirk Harris
J. Kirk Harris

19 January 2022 in Current Opinion in Pediatrics
Verified
Journal Article
Closed access
RKRacha T. Khalaf
Racha T. Khalaf
SFSteven L. Ford
Steven L. Ford
Purpose of review: Parenteral nutrition is an integral part of the care of infants in the neonatal ICU. However, prolonged use of parenteral nutrition can be associated with adverse outcomes, most notably parenteral nutrition-associated liver disease, now known as intestinal failure-associated liver disease (IFALD). This review highlights pertinent developments in the epidemiology of IFALD as it pertains to neonates and showcases recent advances in the pathophysiology, treatment, and outcomes of neonates with IFALD. Recent findings: The role of intravenous lipid emulsions in the pathogenesis, prevention, and treatment of IFALD remains a target for investigative studies. Recent data continues to support the use of fish-oil based intravenous lipids, but its use is limited due to concerns for essential fatty acid deficiency. Use of soy-based lipids and mixed lipids is not wrought with such concerns as these are often used at greater doses but their use is limited due to higher proinflammatory fatty acid content, increased phytosterols and decreased antioxidants, risk factors for the development of IFALD. Summary: Hepatic complications may limit the use of parenteral nutrition in the neonatal ICU. However, the pathophysiology of IFALD is continuing to be further elucidated and novel targets are being developed for the treatment of IFALD. As noninvasive disease monitoring strategies continue to be developed, early enteral nutrition ameliorates the risk of IFALD and should be considered when possible.

28 March 2023 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
RGRekha Gupta
Rekha Gupta
RKRacha Khalaf
Racha Khalaf
JMJohn Morrison
John Morrison
EAErnest Amankwah
Ernest Amankwah
WRWenly Ruan
Wenly Ruan
DTDavid M Troendle
David M Troendle